Global medical technology firm Hill-Rom acquired medical diagnostic devices manufacturer Welch Allyn in a cash and stock deal valued at $2.5bn.
Under the agreement announced in June, Welch Allyn shareholders received $1.625bn in cash and nearly 8.1 million newly issued shares of Hill-Rom common stock.
Hill-Rom president John Greisch said: "We are excited to officially welcome our 2,500 Welch Allyn colleagues to the Hill-Rom family.
"Our companies share similar legacies of innovation, quality and employees who are passionate about enhancing outcomes for patients and caregivers."
A Spanish cancer patient received a titanium 3D-printed sternum and rib implant, designed and manufactured by an Australian company.
The 54-year-old Spaniard needed his sternum and a portion of his rib cage replaced as he was suffering from a chest wall sarcoma, a type of tumour that grows in and around the rib cage.
In order to prevent the cancer from spreading, doctors had to remove the sternum and part of the patient's rib cage.
This technology was designed and developed in collaboration between Anatomics, a Melbourne-based medical device company, and CSIRO's 3D printing facility, Lab 22, at Clayton.
Scientists at University of Southern California (USC) developed a prosthetic implant to help a disabled brain encode memories from being forgotten.
The prosthesis, which includes a small array of electrodes implanted into the brain, gives new hope for dementia and brain-damaged patients who are suffering from memory loss.
According to researchers, the new implant was tested successfully in animals and is now being evaluated on human brains.
The implant was designed at USC and tested at Wake Forest Baptist Medical Center in Winston-Salem, as part of their decade-long collaboration.
Ireland-based pharmaceutical firm Allergan entered an agreement to acquire US-based medical device firm AqueSys for $300m.
AqueSys is focused on developing ocular implants that reduce intraocular pressure (IOP) associated with glaucoma.
The deal will include regulatory approval and commercialisation milestone payments related to AqueSys' lead development programmes, including XEN45.
Global healthcare firm Abbott acquired US-based clinical stage medical device company Tendyne for $250m.
The deal was first announced in July, and Abbott acquired the equity of Tendyne that it did not already own for $225m upfront, which brought the total transaction value to $250m.
Abbott also made potential future payments related to regulatory milestones.
The US Food and Drug Administration (FDA) granted approval for Bayer HealthCare's Betaconnect, an electronic autoinjector developed to treat relapsing-remitting multiple sclerosis (RRMS).
Beginning in early 2016, the autoinjector will be available exclusively to Betaseron (interferon beta-1b) patients.
Betaseron is a prescription medicine used to reduce the number of relapses in people with relapsing forms of multiple sclerosis.
Betaconnect provides customisable injection speed and depth settings, which allow patients to inject softly with precision at the touch of a button.
Agilent Technologies signed a definitive agreement to acquire Seahorse Bioscience, a manufacturer of instruments and assay kits for measuring cell metabolism and bioenergetics, for $235m.
Headquartered in Billerica, Massachusetts, US, Seahorse Bioscience develops analysers that provide researchers with a better understanding of cell health, function, signalling, and how the cell may be affected by the introduction of a specific drug, by offering real-time kinetics to unlock essential cellular bioenergetics data.
In particular, XF technology is being used to research the role of cell metabolism in neurodegeneration, ageing, cancer, cardiovascular disease, cell physiology, toxicology, hepatobiology, immunology, infectious diseases, mitochondrial diseases, model organisms, obesity, diabetes, metabolic disorders, as well as screening and translational medicine.
Irish medical technology firm Medtronic completed the acquisition of US-based medical device firm Medina Medical for approximately $150m.
The transaction also includes additional payments based on achievement of key milestones.
Medtronic already owned a stake in Medina Medical prior to this deal, which is expected to allow the company to have a pre-tax gain in the second quarter of fiscal year 2016.
Medina Medical is involved in commercialising modern treatments for vascular abnormalities of the brain, including cerebral aneurysms.